Neurizon Therapeutics Limited (ASX: NUZ) — Perfil da empresa, notícias e dados financeiros
Neurizon Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases.
Neurizon Therapeutics Limited
Neurizon Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's primary drug candidate, NUZ-001, is an oral small-molecule therapeutic targeted at treating amyotrophic lateral sclerosis, also known as motor neurone disease. The candidate is evaluated in Phase 2/3 clinical trials, including as Regimen I within the HEALEY ALS Platform Trial across clinical sites in the United States, following completed Phase 1 and open-label extension studies in Australia. Beyond its primary clinical program in amyotrophic lateral sclerosis, the company evaluates the therapeutic potential of its drug candidate across broader neurodegenerative disease applications.
Resumo
Operações
Produtos e/ou serviços de Neurizon Therapeutics Limited
- Platform Trial Program: Evaluation of an oral drug candidate in an adaptive Phase 2/3 study as Regimen I within the HEALEY ALS Platform Trial across 78 clinical sites in the United States for amyotrophic lateral sclerosis.
- Phase 1 Clinical Studies: Execution of Phase 1 and 12-month open-label extension clinical trials in Australian patient cohorts evaluating drug safety, tolerability, functional decline, survival outcomes, and respiratory metrics in motor neurone disease.
- Preclinical Research Pipeline: Preclinical research and efficacy modeling of small-molecule mTOR pathway modulators aimed at addressing neurodegenerative mechanisms across broader central nervous system disorders beyond motor neurone disease.
- Pharmaceutical Ingredient Manufacturing: Chemistry, manufacturing, and controls operations covering active pharmaceutical ingredient synthesis, cGMP compliance, formulation development, and supply chain management for global clinical trial requirements.
- Regulatory Operations: Preparation and maintenance of Investigational New Drug applications, Investigational Medicinal Product Dossiers, and health authority interactions with regulatory agencies including the United States Food and Drug Administration.
- Strategic Commercial Partnerships: Commercial strategy development, scientific due diligence, and global licensing engagement with international biopharmaceutical organizations, clinical contract research networks, academic institutions, and neurodegenerative disease advocacy groups.
equipe executiva do Neurizon Therapeutics Limited
- Dan O'ConnellChief Financial Officer
- Chris-Carol BremerChief Executive Officer
- John ClarkChief Operating Officer
- Gary PittHead of Chemistry
- James RixsonHead of Production
- Herbert BrinkmanHead of Manufacturing
- Lidija DamjanovicHead of Market Engagement & Corporate Affairs
- Chris FreitagChief Medical Advisor
- Martin EngelHead of Scientific & Commercial Partnerships
- Linda McBrideHead of Regulatory
Últimas notícias sobre a Neurizon Therapeutics Limited
Neurizon Therapeutics secures NIH grant for ALS trial
AustraliaNeurizon accelerates trial timelines as enrolment completes
AustraliaNeurizon beats schedule for key ALS trial milestone
AustraliaNeurizon secures ethics approval for ALS liquid study
AustraliaNeurizon unveils preclinical protein clearance data
AustraliaNeurizon initiates patient dosing in HEALEY ALS platform trial
Australia
Comunicados recentes
O que a Neurizon Therapeutics Limited (NUZ) comunicou ao mercado, do mais recente para o mais antigo.
- Notification of cessation of securities - NUZ
- Updated Investor Presentation and Webinar Reminder
- FDA Type C Feedback, HEALEY trial potentially registrationalFato relevante
- Dr Chris Bremer commences as Neurizon CEO
- Application for quotation of securities - NUZ
- Neurizon executes long-term supply agreement with ElancoFato relevante
Principais indicadores financeiros
Resultados divulgados pela Neurizon Therapeutics Limited, em AUD.
- Cap. de mercado
- 68,1 mi
- Receita (TTM)
- 17,6 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.0
- Dividend yield
- —
- Margem de lucro
- -61.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 17,6 mi | -27,8 mi | -10,7 mi | |
| — | -18,5 mi | -16,6 mi | |
| — | -6,7 mi | -9 mi | |
| 873,7 mil | -6,7 mi | -9 mi |